Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

NCT03171025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

NCT03532451 ·Status: COMPLETED ·Phase: PHASE1

Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

NCT03421652 ·Status: COMPLETED ·Phase: PHASE2

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

NCT04149574 ·Status: TERMINATED ·Phase: PHASE3

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

NCT02387996 ·Status: COMPLETED ·Phase: PHASE2

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

NCT05496192 ·Status: WITHDRAWN ·Phase: PHASE2

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

NCT02632409 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

NCT03519256 ·Status: TERMINATED ·Phase: PHASE2

A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

NCT04506554 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

NCT01314664 ·Status: TERMINATED

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04164082 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Basal Like Bladder Cancer : Signature and Therapeutic

NCT02648100 ·Status: UNKNOWN

Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT03167151 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

NCT03785925 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

NCT06534983 ·Status: RECRUITING ·Phase: PHASE2

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)

NCT04876313 ·Status: UNKNOWN ·Phase: PHASE2

Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

NCT03993249 ·Status: UNKNOWN ·Phase: PHASE2

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NCT06237920 ·Status: RECRUITING ·Phase: PHASE2

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

NCT03617913 ·Status: COMPLETED ·Phase: PHASE2

Drug Screening Using IMD in Bladder Cancer

NCT06204614 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

NCT05687721 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

NCT02496208 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

NCT04610671 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)

NCT06551233 ·Status: RECRUITING ·Phase: PHASE1

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05014139 ·Status: TERMINATED ·Phase: PHASE1